Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in combination with TACE in Patients with Locoregional HCC - EMERALD-3

Study identifier:D910VC00001

ClinicalTrials.gov identifier:NCT05301842

EudraCT identifier:2021-003822-54

CTIS identifier:N/A

Recruiting

Official Title

A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with TACE Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)

Medical condition

Hepatocellular Carcinoma

Phase

Phase 3

Healthy volunteers

No

Study drug

Tremelimumab, Durvalumab, Lenvatinib

Sex

All

Estimated Enrollment

725

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 28 Mar 2022
Estimated Primary Completion Date: 31 Dec 2025
Estimated Study Completion Date: 26 Feb 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria